Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of HMPL-523 in Healthy Male Subjects
NCT05781906Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sovleplenib in immune thrombocytopenia (ITP), sponsored by HUTCHMED. Primary endpoint: Human Mass Balance. Started Feb 2023; status: completed.
02
Drugs
sovleplenib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05781906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781906.